

1 **Supplementary information (SI)**

2

3 **Extractable organofluorine analysis in pooled human serum and**
4 **placental tissue from an Austrian sub-population – a mass balance**
5 **analysis approach**

6

7 Andreas-Marius Kaiser^{1,2*}, Martin Forsthuber^{2,3}, Rudolf Aro⁴, Anna Kärrman⁴, Claudia
8 Gundacker², Harald Zeisler⁵, Philipp Foessleitner⁶, Hans Salzer⁷, Christina
9 Hartmann¹, Maria Uhl¹, and Leo W.Y Yeung^{4**}

10

11

12 **Affiliations**

13 ¹Environment Agency Austria, Spittelauer Lände 5, A-1090 Vienna, Austria

14 ²Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of
15 Vienna, A-1090 Vienna, Austria

16 ³Department of Environmental Health, Center for Public Health, Medical University of Vienna, A-1090
17 Vienna, Austria

18 ⁴Man-Technology-Environment Research Centre (MTM), Örebro University, Örebro, 701 82, Sweden

19 ⁵Department of Obstetrics and Gynecology, Medical University Vienna, A-1090 Vienna, Austria

20 ⁶ Department of Gynecology and Obstetrics, University Hospital St. Poelten, A-3100 St. Poelten,
21 Austria

22 ⁷ Clinic for Pediatrics and Adolescent Medicine, University Hospital Tulln, A-3430 Tulln, Austria

23

24

25 **Corresponding authors**

26 *Andreas-Marius Kaiser, e-mail: Andreas.Kaiser@umweltbundesamt.at

27 **Leo W.Y. Yeung, e-mail: Leo.Yeung@oru.se

Table of Content

- P.3 PFAS concentrations in pooled samples
- P.6 Figure S1: Heatmap representing Spearman correlations [...]
- P.7 Limits of detection (LOD) and limits of quantification (LOQ)
- P.7 Table S1: For the serum pool samples the limits of detection (LOD) [...]
- P.9 Table S2: For the placental tissue pool samples the limits of detection (LOD) [...]
- P.12 Concentrations of the individual serum and placental tissue pool samples
- P.12 Table S3: PFAS concentrations of the single maternal serum pool samples matS-A to matS-E
- P.14 Table S4: PFAS concentrations of the single maternal serum pool samples matS-F to matS-J
- P.16 Table S5: PFAS concentrations of the single maternal serum pool samples matS-K to matS-O
- P.18 Table S6: PFAS concentrations of the single maternal serum pool samples matS-P to matS-U
- P.21 Table S7: PFAS concentrations of the placental pool tissue samples plaT-A to plaT-E
- P.23 Table S8: PFAS concentrations of the placental pool tissue samples plaT-F to plaT-J
- P.25 Table S9: PFAS concentrations of the placental pool tissue samples plaT-K to plaT-M
- P.27 Table S10: PFAS concentrations of the cord serum pool samples cordS-B to cordS-H
- P.30 Table S11: PFAS concentrations of the cord serum pool samples cordS-K to cordS-U
- P.32 Table S12: Blanks (BW): for BW 1 and BW 2 3 mL Milli Q Water (MQ) [...]
- P.34 Table S13: Blanks (BW): for BW 6 and BW 7 3 mL Milli Q Water (MQ) [...]
- P.36 Table S14: Blanks (BW): for BW 11 and BW 12 3 mL Milli Q Water (MQ) [...]
- P.38 Table S15: Blanks (BW): for BW 1 and BW 3 3 mL Milli Q Water (MQ) [...]
- P.41 Extractable organofluorine (EOF) concentrations of the samples
- P.41 Table S16: Identified EOF in ng F/mL in maternal serum (matS)
- P.42 Table S17: Identified EOF in ng F/mL in placental tissue (plaT)
- P.42 Table S18: Identified EOF in ng F/mL in cord serum (cordS)
- P.44 Table S19: Detail information on the sample pooling
- P.45 Table S20: The comparison of EOF concentrations in ng F/mL of the present study with previous studies
- P.46 Correlation analyses and scatter plots
- P.46 Figure S2: Correlation between PFBA and EOF-CIC, [...]
- P.47 Figure S3: Correlation between MeFOSAA and EOF-CIC, [...]
- P.48 Figure S4: Correlation between 3:3 FTCA and EOF-CIC, [...]
- P.49 Figure S5: Correlation between PFOS and EOF-CIC, [...]
- P.50 Figure S6: Correlation between 6:2 FTSA and EOF-CIC, [...]
- P.51 Figure S7: Correlation between PFECHS and EOF-CIC in matS
- P.52 Abbreviations
- P.56 References

32 **PFAS concentrations in pooled samples**

33 The average sum concentration (recovery corrected) of the 61 monitored PFAS
34 ($\sum_{61}\text{PFAS}$) in maternal serum (matS) was 4.8 ng/mL (ranging from 2.7 to 9.6 ng/mL;
35 $p = 21$), 1.6 ng/g (0.73–3.2 ng/g; $p = 13$) in placental tissue (plaT) and 2.0 ng/mL
36 (0.35–3.3 ng/mL; $p = 11$) in cord serum (cordS).

37

38 Of the 61 PFAS included in this study, 21 were detected at least once in maternal
39 serum samples. The PFCAs were the dominant class – making up 46.8% of the
40 $\sum_{61}\text{PFAS}$. The PFCAs with the highest concentrations were PFOA (1.5 ng/mL
41 (± 0.89)), perfluorononanoic acid (PFNA, 0.38 ng/mL (± 0.20)) and perfluorodecanoic
42 acid (PFDA, 0.21 ng/mL (± 0.13)). These compounds were found in 100% of the
43 maternal serum samples. Perfluorohexanoic acid (PFHxA, 0.012 ng/mL (± 0.0081))
44 and perfluoroheptanoic acid (PFHpA, 0.027 ng/mL (± 0.023)) were found in 66.7%
45 and 90.5% of the maternal serum samples. The PFSA were the second largest class
46 of PFAS (43.2%) – driven by linear PFOS (1.6 ng/mL (± 1.0)), branched PFOS
47 (0.43 ng/mL (± 0.22)), perfluorohexane sulfonate (PFHxS, 0.46 ng/mL (± 0.15)) and
48 perfluoroheptane sulfonate (PFHpS, 0.053 ng/mL (± 0.030)). These compounds were
49 found in all of the maternal serum samples. Perfluorobutane sulfonate (PFBS, 0.010
50 ng/mL (± 0.0056)) and perfluoropentane sulfonate (PFPeS, 0.0093 ng/mL (± 0.0077))
51 were found in 90.5% and 81.0% of the maternal serum samples. PFAA precursors
52 together accounted for 10.0% of the $\sum_{61}\text{PFAS}$. N-methylperfluoro-n-octane
53 sulfonamido acetic acid (MeFOSAA) and N-ethyl-perfluoro-n-octane sulfonamido
54 acetic acid (EtFOSAA) were detected at trace levels (below 0.19 ng/mL) in 47.6%
55 and 9.5% of samples. Of the other PFAS, perfluoro-4-ethylcyclohexane sulfonate
56 (PFECHS) and ADONA were detected in 81.0% and 57.1% of samples respectively,
57 with an average concentration of 0.038 ng/mL (± 0.0021) and 0.022 ng/mL (± 0.020).

58 In the placental tissue samples 23 different PFAS were detected at least once. The
59 PFCAs were the dominant class in the placental tissue as well – making up 49.4% of
60 the \sum_{61} PFAS. The PFCAs with the highest concentrations were PFOA (0.44 ng/mL
61 (± 0.31)), PFNA (0.13 ng/mL (± 0.067)) and PFDA (0.068 ng/mL (± 0.032)). These
62 compounds were found in all of the placental tissue samples. Perfluorobutanoic acid
63 (PFBA, 0.025 ng/mL (± 0.018)) and PFHpA (0.011 ng/mL (± 0.0064)) were found in
64 53.8% and 76.9% of the maternal serum samples. Long-chain PFCAs with carbon
65 chains ranging from C11 to C14 were found in 100% of the samples except for
66 perfluorotridecanoic acid (PFTrDA) which was detected in 92.3% of the placental
67 tissue samples (perfluoroundecanoic acid (PFUnDA): 0.051 ng/mL (± 0.030),
68 perflurorododecanoic acid (PFDoDA): 0.024 ng/mL (± 0.018), PFTrDA: 0.022 ng/mL
69 (± 0.017), perfluorotetradecanoic acid (PFTeDA): 0.039 ng/mL (± 0.029)). The PFSAs
70 were the second largest class of PFAS – linear PFOS (0.53 ng/mL (± 0.26)),
71 branched PFOS (0.094 ng/mL (± 0.031)), PFHxS (0.11 ng/mL (± 0.045)), PFHpS
72 (0.014 ng/mL (± 0.0067)), perfluorodecanoic sulfonate (PFDS, 0.0043 ng/mL
73 (± 0.012)) and perflurorododecanoic sulfonate (PFDoDS, 0.00060 ng/mL (± 0.00020)).
74 PFHxS, PFHpS, linear PFOS and branched PFOS were found in 100% and PFDS
75 and PFDoDS in 7.7% of the placental tissue samples. PFAA precursors together
76 accounted for 10.1% of the \sum_{61} PFAS. MeFOSAA and EtFOSAA were detected at
77 trace levels (below 0.012 ng/mL) in 100% and 69.2% of samples. The two
78 polyfluoroalkyl phosphoric acid diesters (diPAP), 6:2 diPAP and 8:2 diPAP, were
79 detected at trace levels (below 0.040 ng/mL) in 15.4% and 7.7% of samples,
80 respectively.


81
82 Of the 61 compounds monitored, 18 were found in the cord serum samples. The
83 PFCAs were the dominant class in the cord serum samples as well – making up

84 56.4% of the \sum_{61} PFAS. The PFCAs with the highest concentrations were PFOA
85 (0.85 ng/mL (\pm 0.37)), PFNA (0.15 ng/mL (\pm 0.072)) and PFDA (0.050 ng/mL
86 (\pm 0.023)). These compounds were found in 100% of the cord serum samples except
87 for PFDA which was found in 90.9% of the samples. PFHxA (0.019 ng/mL (\pm 0.0083))
88 and PFHpA (0.032 ng/mL (\pm 0.022)) were found in 18.2% and 90.9% of the cord
89 serum samples, respectively. The longer chain compounds, PFUnDA (0.034 ng/mL
90 (\pm 0.017)) and PFDoDA (0.010 ng/mL (\pm 0.0060)) were found in 100% and 54.5% of
91 the cord serum samples. The PFSAs were the second largest class of PFAS in the
92 cord serum as well 33.3% – driven by linear PFOS (0.38 ng/mL (\pm 0.20)), branched
93 PFOS (0.18 ng/mL (\pm 0.082)), PFHxS (0.22 ng/mL (\pm 0.081)) and PFHpS
94 (0.018 ng/mL (\pm 0.010)). Linear and branched PFOS as well as PFHxS were found in
95 100% and PFHpS in 90.9% of the cord serum samples. PFBS (0.0065 ng/mL
96 (\pm 0.0035)) and PFPeS (0.0046 ng/mL (\pm 0.0026)) were found both in 81.8% of cord
97 serum samples. PFAA precursors together accounted for 10.4% of the \sum_{61} PFAS.
98 MeFOSAA and EtFOSAA were detected at trace levels (below 0.17 ng/mL) in 45.5%
99 and 18.2% of samples. Of the other PFAS, PFECHS and ADONA were detected in
100 90.9% and 72.7% of samples respectively, with an average concentration of
101 0.0027 ng/mL (\pm 0.0019) and 0.015 ng/mL (\pm 0.010), respectively. The limits of
102 detection (LOD) and limits of quantification (LOQ) for the individual sample volumes
103 are provided in Table S1 and Table S2. Table S3 to Table S11 provide individual PFAS
104 concentrations for all sample pools, and Table S12 to Table S15 provide the
105 individual PFAS concentrations for all blanks.

106

107 Figure S1 shows the Spearman correlations for the pooled maternal serum and their
108 related pooled cord serum samples (compounds at least detected in 4 related
109 samples, except for EtFOSAA which was detected only in two related samples above

110 the LOD). Statistically significant positive correlations were observed for 9 PFAS,
111 which include perfluoroheptanoic acid (PFHpA), perfluorononanoic acid (PFNA),
112 perfluorodecanoic acid (PFDA), perfluorohexanoic sulfonate (PFHxS), L-PFOS, 7:3
113 FTCA, ADONA, MeFOSAA and EtFOSAA. No statistically significant differences
114 were found in cord serum between males and females for any of the detected PFAS
115 except for perfluoroheptanoic sulfonate (PFHpS; $p < 0.02$).
116



117
118 Figure S1: Heatmap representing Spearman correlations between the pooled maternal serum ($p = 10$)
119 and their related pooled cord serum ($p = 10$), correlations that were statistically significant are marked
120 additionally with stars (* < 0.05 ; ** < 0.01 ; and *** < 0.001).
121
122

123 **Limits of detection (LOD) and limits of quantification (LOQ)**

124

125 Table S1: For the serum pool samples the limits of detection (LOD) and the limits of quantification
126 (LOQ) were calculated respecting their specific sample volumes and recoveries by the applied SPE-
127 WAX method.

Lowest and highest LOD and lowest and highest LOQ for serum samples in pg/mL				
Compound	Lowest LOD	Lowest LOQ	Highest LOD	Highest LOQ
PFBA	4.0	8.0	70	140
PFPeA	2.2	4.4	30	60
PFHxA	2.0	4.0	40	80
PFHpA	3.5	7.0	65	130
PFOA	2.5	5.0	45	90
PFNA	0.70	1.4	15	30
PFDA	6.0	12	100	200
PFUnDA	0.70	1.4	13	26
PFDoDA	2.0	4.0	35	70
PFTrDA	1.5	3.0	20	40
PFTDA	4.0	8.0	70	140
PFHxDA	65	130	950	1900
PFOcDA	48138	96277	924256	1848000
PFBS	0.30	0.60	5.0	10
PFPeS	0.30	0.60	5.0	10
PFHxS	2.5	5.0	40	80
PFHpS	0.30	0.60	5.0	10.0
L-PFOS	3.0	6.0	50	100
PFNS	0.50	1.0	8.0	16
PFDS	0.35	0.70	5.5	11
PFDoDS	7.0	14	100	200
PFECHS	0.25	0.50	4.5	9.0
FBSA	1.0	2.0	20	40
MeFBSA	8.0	16	120	240

FHxSA	0.70	1.4	11	22
MeFHxSA	2.0	4.0	35	70
FOSA	0.30	0.60	5.0	10
MeFOSA	12.5	25	250	500
EtFOSA	16	32	300	600
MeFOSE	15	30	280	560
EtFOSE	17	34	325	650
3:3 FTCA	1.6	3.2	22	44
5:3 FTCA	0.70	1.4	10	20
7:3 FTCA	0.85	1.7	12	24
6:2 FTUCA	0.80	1.6	12	24
8:2 FTUCA	0.40	0.80	6.5	13
10:2 FTUCA	0.50	1.0	8.5	17
4:2 FTSA	0.20	0.40	3.75	7.5
6:2 FTSA	0.60	1.2	7.5	15
8:2 FTSA	0.18	0.36	3.2	6.4
10:2 FTSA	5.0	10	100	200
PFHxPA	0.75	1.5	15	30
PFOPA	4800	9600	92000	184000
PFDPA	25	50	340	680
6:6 PFPiA	2.4	4.8	38	76
6:8 PFPiA	900	1800	12500	25000
8:8 PFPiA	130000	260000	2485000	4970000
8:2 Cl-PFESA	0.40	0.80	6.0	12
6:2 Cl-PFESA	0.25	0.50	3.75	7.5
ADONA	0.625	1.25	10	20
HFPO-DA (GenX)	7.5	15	100	200
MeFOSAA	1.25	2.5	25	50
EtFOSAA	5.0	10	42	84
diSAmPAP	5900	11800	47000	94000
6:2 monoPAP	43500	87000	347000	694000
8:2 monoPAP	11000	22000	87500	175000

10:2 monoPAP	14	28	100	200
6:2 diPAP	28	56	225	450
8:2 diPAP	480	960	3900	7800
6:2/8:2 diPAP	550	1100	4250	8500
10:2 diPAP	22000	44000	174000	348000
PFOS-branch Σ				

128

129

130 Table S2: For the placental tissue pool samples the limits of detection (LOD) and the limits of
 131 quantification (LOQ) were calculated respecting their specific sample masses and recoveries - "n.a."
 132 means not available, since no peak was observed caused by a shift of the chromatogram.

Lowest and highest LOD and lowest and highest LOQ for placental tissue in pg/g				
Compound	Lowest LOD	Lowest LOQ	Highest LOD	Highest LOQ
PFBA	0.55	1.1	2.2	4.4
PFPeA	0.35	0.70	1.4	2.8
PFHxA	0.40	0.80	1.5	3.0
PFHpA	0.85	1.7	3.5	7.0
PFOA	0.70	1.4	3.0	6.0
PFNA	0.25	0.50	1.0	2.0
PFDA	1.8	3.6	7.0	14
PFUnDA	0.45	0.90	1.8	3.6
PFDoDA	0.40	0.80	1.5	3.0
PFTrDA	0.10	0.20	0.40	0.80
PFTDA	0.10	0.20	0.40	0.80
PFHxDA	1.4	2.8	5.5	11
PFOcDA	130	260	500	1000
PFBS	0.050	0.10	0.20	0.40
PFPeS	0.070	0.14	0.26	0.52
PFHxS	0.60	1.2	2.5	5.0
PFHpS	0.065	0.13	0.25	0.50
L-PFOS	0.50	1.0	2.0	4.0
PFNS	n.a.	n.a.	n.a.	n.a.

PFDS	0.050	0.10	0.20	0.40
PFDoDS	0.20	0.40	0.85	1.7
PFECHS	n.a.	n.a.	n.a.	n.a.
FBSA	0.20	0.40	0.80	1.6
MeFBSA	0.80	1.6	3.5	7.0
FHxSA	0.20	0.40	0.70	1.4
MeFHxSA	0.70	1.4	2.8	5.6
FOSA	0.20	0.40	0.70	1.4
MeFOSA	10	20	38	76
EtFOSA	45	90	180	360
MeFOSE	3900	7800	15500	31000
EtFOSE	n.a.	n.a.	n.a.	n.a.
3:3 FTCA	0.20	0.40	0.85	1.7
5:3 FTCA	0.075	0.15	0.30	0.60
7:3 FTCA	0.22	0.44	0.95	1.9
6:2 FTUCA	0.15	0.30	0.60	1.2
8:2 FTUCA	0.20	0.40	0.75	1.5
10:2 FTUCA	0.375	0.75	1.5	3.0
4:2 FTSA	0.030	0.060	0.12	0.24
6:2 FTSA	0.070	0.14	0.275	0.55
8:2 FTSA	0.034	0.068	0.14	0.28
10:2 FTSA	n.a.	n.a.	n.a.	n.a.
PFHxPA	0.32	0.64	1.25	2.5
PFOPA	15	30	60	120
PFDPa	30	60	120	240
6:6 PFPiA	6.0	1.2	2.5	5.0
6:8 PFPiA	100	200	430	860
8:8 PFPiA	300	600	1150	2300
8:2 Cl-PFESA	0.050	0.10	0.20	0.40
6:2 Cl-PFESA	n.a.	n.a.	n.a.	n.a.
ADONA	0.18	0.36	0.85	1.7
HFPO-DA (GenX)	90	180	350	700

MeFOSAA	0.30	0.60	1.0	2.0
EtFOSAA	1.2	2.4	5.0	10
diSAmPAP	2.0	4.0	8.25	16.5
6:2 monoPAP	7000	14000	28000	56000
8:2 monoPAP	1750	3500	7000	14000
10:2 monoPAP	1900	3800	7600	15200
6:2 diPAP	2.5	5.0	10	20
8:2 diPAP	0.75	1.5	3.0	6.0
6:2/8:2 diPAP	3.75	7.5	14	28
10:2 diPAP	250	500	1000	2000
PFOS-branch Σ				

133

134

135

136 **Concentrations of the individual serum and placental tissue pool samples**

137

138 Table S3: PFAS concentrations of the single maternal serum pool samples matS-A to matS-E in
 139 ng/mL (not concentrated value, so the concentrations represents the mean of each single sample in
 140 the respective pool) – the number in the “()” represents the number of samples which were pooled
 141 together

Summary of the concentrations [ng/mL] of pooled maternal serum from A-E					
Compound	matS-A (3)	matS-B (2)	matS-C (3)	matS-D (3)	matS-E (1)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.011	<LOQ	0.015	0.012	<LOQ
PFHpA	0.017	0.042	0.020	0.028	<LOD
PFOA	1.56	1.82	1.43	1.35	0.97
PFNA	0.98	0.23	0.34	0.36	0.56
PFDA	0.29	0.13	0.19	0.18	0.67
PFUnDA	0.19	0.060	0.063	0.045	0.38
PFDoDA	0.013	<LOD	0.011	0.0092	0.092
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0073	0.014	0.010	0.0029	<LOD
PFPeS	0.0087	0.016	0.018	0.0054	<LOD
PFHxS	0.44	0.45	0.58	0.27	0.48
PFHpS	0.037	0.038	0.054	0.044	0.10
L-PFOS	0.77	0.93	1.49	1.07	4.63
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	<LOD	0.0032	0.0024	0.0035	<LOD
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	n.a.	n.a.	n.a.	n.a.	n.a.

FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	0.016	0.012	<LOD	0.0068	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTS	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPA	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	<LOD	0.0056	0.024	<LOD	0.0736
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	0.0058	<LOD	<LOQ	0.012	<LOD
EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD
diSAMPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.

10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.28	0.30	0.50	0.36	0.50

142

143 Table S4: PFAS concentrations of the single maternal serum pool samples matS-F to matS-J in ng/mL
 144 (not concentrated value, so the concentrations represents the mean of each single sample in the
 145 respective pool) – the number in the “(“) represents the number of samples which were pooled
 146 together

Summary of the concentrations [ng/mL] of pooled maternal serum from F-M					
Compound	matS-F (4)	matS-G (2)	matS-H (3)	matS-I (1)	matS-J (2)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.011	0.025	<LOQ	<LOD	0.016
PFHpA	0.012	<LOQ	<LOQ	<LOD	0.056
PFOA	0.78	0.52	1.41	3.62	4.17
PFNA	0.21	0.15	0.50	0.64	0.51
PFDA	0.12	0.048	0.30	0.23	0.34
PFUnDA	0.043	0.010	0.080	0.033	0.14
PFDoDA	0.0071	0.0040	0.011	<LOD	0.042
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0063	0.011	0.0073	0.010	0.022
PFPeS	0.0040	0.011	0.0038	<LOD	0.0051
PFHxS	0.25	0.72	0.39	0.59	0.74
PFHpS	0.034	0.068	0.033	0.075	0.061
L-PFOS	0.91	1.27	1.45	1.05	2.72
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD

PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0023	n.n.	0.011	n.n.	0.0055
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	n.a.	n.a.	n.a.	n.a.	n.a.
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	0.0040	<LOD	0.013	<LOD	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPa	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	0.0071	0.0060	<LOD	<LOD	<LOQ
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.

MeFOSAA	0.028	<LOD	0.020	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOQ	<LOD	<LOD
diSAmPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.23	0.36	0.38	0.60	0.59

147

148

149 Table S5: PFAS concentrations of the single maternal serum pool samples matS-K to matS-O in
 150 ng/mL (not concentrated value, so the concentrations represents the mean of each single sample in
 151 the respective pool) – the number in the “()” represents the number of samples which were pooled
 152 together

Summary of the concentrations [ng/mL] of pooled maternal serum from K-O					
Compound	matS-K (3)	matS-L (3)	matS-M (2)	matS-N (3)	matS-O (2)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.012	0.0088	<LOD	<LOD	<LOD
PFHpA	0.021	0.026	<LOQ	0.090	0.075
PFOA	1.69	1.50	1.47	1.38	2.11
PFNA	0.44	0.23	0.27	0.27	0.65
PFDA	0.22	0.12	0.15	0.12	0.31
PFUnDA	0.096	0.050	0.052	0.049	0.11
PFDoDA	0.013	<LOD	<LOD	0.014	0.050
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.

PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	0.0078	0.0062	0.018	0.0096
PPPeS	<LOD	<LOQ	<LOD	0.010	0.032
PFHxS	0.44	0.54	0.48	0.33	0.68
PFHpS	0.046	0.038	0.032	0.058	0.16
L-PFOS	1.38	0.86	1.51	1.02	3.97
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0051	0.0033	<LOQ	0.0022	0.0033
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	n.a.	n.a.	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	<LOD	<LOD	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	0.021	<LOD	0.0086	0.010	0.0097
6:2 FTUCA	<LOD	<LOD	<LOQ	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	n.a.	n.a.	<LOD	<LOD	<LOD
8:2 FTSA	<LOD	<LOD	<LOD	0.0060	<LOD
10:2 FTSA	<LOD	<LOD	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPa	n.a.	n.a.	n.a.	n.a.	n.a.

6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	0.027	0.033	0.041	0.019	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
N-MeFOSAA	<LOD	<LOD	<LOQ	<LOQ	0.030
N-EtFOSAA	<LOD	<LOD	<LOD	<LOD	0.19
diSAmPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.40	0.33	0.52	0.37	1.22

153

154 Table S6: PFAS concentrations of the single maternal serum pool samples matS-P to matS-U in
 155 ng/mL (not concentrated value, so the concentrations represents the mean of each single sample in
 156 the respective pool) – the number in the “()” represents the number of samples which were pooled
 157 together

Summary of the concentrations [ng/mL] of pooled maternal serum from P-U						
Compound	matS-P (3)	matS-Q (3)	matS-R (3)	matS-S (3)	matS-T (3)	matS-U (2)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	<LOQ	<LOQ	<LOD	<LOD	<LOQ	<LOD
PFHpA	0.013	0.013	<LOQ	0.021	0.031	<LOQ
PFOA	0.72	0.73	1.20	1.12	1.29	0.94
PFNA	0.27	0.24	0.41	0.19	0.31	0.22
PFDA	0.15	0.14	0.30	0.096	0.18	0.12

PFUnDA	0.072	0.081	0.078	0.042	0.12	0.078
PFDoDA	0.017	<LOD	<LOD	<LOD	0.017	0.023
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0074	0.0090	0.0042	0.017	0.021	0.0040
PPeS	0.0053	0.0034	0.0044	0.012	0.016	0.0037
PFHxS	0.30	0.38	0.26	0.32	0.45	0.49
PFHpS	0.043	0.031	0.020	0.033	0.042	0.061
L-PFOS	1.20	0.96	1.21	0.76	1.38	2.07
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0043	0.0029	0.0034	0.0034	0.0050	0.0034
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	0.14	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	<LOQ	<LOQ	0.010	<LOQ	0.0051	<LOD
6:2 FTUCA	<LOD	<LOD	0.0054	<LOD	<LOQ	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	0.0020	<LOD	0.0057	<LOD	<LOD	<LOD

8:2 FTSA	0.016	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	<LOD	<LOD	0.0072	<LOD	0.020	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	0.011	0.017	<LOD	<LOD	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
diSAMPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.35	0.21	0.28	0.25	0.34	0.68

158

159

160

161

162 Table S7: PFAS concentrations of the placental pool tissue samples plaT-A to plaT-E in ng/g (not
 163 concentrated value, so the concentrations represents the mean of each single sample in the
 164 respective pool) – the number in the “()” represents the number of samples which were pooled
 165 together

Summary of the concentrations [ng/g] of pooled placental tissue from A-E					
Compound	plaT-A (3)	plaT-B (2)	plaT-C (3)	plaT-D (3)	plaT-E (1)
PFBA	0.031	0.029	<LOD	0.053	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHpA	<LOD	0.0095	0.0077	0.013	0.0038
PFOA	0.35	0.31	0.29	0.47	0.14
PFNA	0.26	0.056	0.085	0.17	0.11
PFDA	0.077	0.031	0.047	0.069	0.12
PFUnDA	0.11	0.024	0.035	0.043	0.10
PFDoDA	0.027	0.013	0.013	0.022	0.070
PFTrDA	0.032	0.016	0.018	0.0049	0.032
PFTDA	0.029	0.023	0.020	0.028	0.090
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeS	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxS	0.080	0.080	0.098	0.13	0.060
PFHpS	0.0076	0.013	0.012	0.016	0.012
L-PFOS	0.27	0.41	0.44	0.52	0.98
PFNS	<LOD	<LOD	n.a.	n.a.	n.a.
PFDS	<LOD	<LOD	<LOD	<LOD	0.0043
PFDoDS	0.0006	<LOD	<LOD	<LOD	<LOD
PFECHS	n.a.	n.a.	n.a.	n.a.	n.a.
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD

FOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	n.a.	n.a.	n.a.	n.a.	n.a.
EtFOSE	n.a.	n.a.	n.a.	n.a.	n.a.
3:3 FTCA	<LOD	0.0007	0.0006	0.0014	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	0.0013	<LOD
7:3 FTCA	0.012	0.012	0.0027	0.035	0.011
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 FTUCA	n.a.	n.a.	n.a.	n.a.	n.a.
4:2 FTSA	0.0098	0.0054	0.0065	0.0088	0.0028
6:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTSA	0.013	0.0068	<LOD	<LOD	0.0042
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPDA	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	n.a.	n.a.	n.a.	n.a.	n.a.
ADONA	<LOD	<LOD	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	0.0076	0.0088	0.0051	0.017	0.0044
EtFOSAA	<LOD	0.0062	0.0036	0.0066	0.0033
diSAMPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 diPAP	<LOD	<LOD	<LOD	0.0049	<LOD

8:2 diPAP	<LOD	<LOD	<LOD	0.0022	<LOD
6:2/8:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.066	0.096	0.081	0.12	0.10

166

167

168 Table S8: PFAS concentrations of the placental pool tissue samples plaT-F to plaT-J in ng/g (not
 169 concentrated value, so the concentrations represents the mean of each single sample in the
 170 respective pool) – the number in the “()” represents the number of samples which were pooled
 171 together

Summary of the concentrations [ng/g] of pooled placental tissue from F-J					
Compound	plaT-F (4)	plaT-G (2)	plaT-H (3)	plaT-I (1)	plaT-J (2)
PFBA	0.021	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHpA	0.0048	<LOD	0.0090	0.010	0.019
PFOA	0.14	0.21	0.36	1.00	1.15
PFNA	0.058	0.073	0.16	0.25	0.16
PFDA	0.026	0.041	0.12	0.087	0.095
PFUnDA	0.020	0.030	0.061	0.035	0.073
PFDoDA	0.0099	0.013	0.026	0.013	0.050
PFTrDA	0.0099	0.0091	0.019	0.0035	0.064
PFTDA	0.021	0.021	0.039	0.017	0.11
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeS	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxS	0.037	0.17	0.059	0.15	0.18
PFHpS	0.0058	0.026	0.0075	0.020	0.025
L-PFOS	0.28	0.86	0.39	0.49	1.07
PFNS	n.a.	n.a.	n.a.	n.a.	n.a.

PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDODS	<LOD	<LOD	<LOD	<LOD	<LOD
PFECHS	n.a.	n.a.	n.a.	n.a.	n.a.
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	n.a.	n.a.	n.a.	n.a.	n.a.
EtFOSE	n.a.	n.a.	n.a.	n.a.	n.a.
3:3 FTCA	0.0005	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	0.0050	0.021	0.011	0.0081	0.017
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 FTUCA	n.a.	n.a.	n.a.	n.a.	n.a.
4:2 FTSA	0.0047	0.0023	0.0058	0.0055	0.0073
6:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTSA	0.0047	0.0031	0.0022	<LOD	0.0078
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPa	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 CI-PFESA	n.a.	n.a.	n.a.	n.a.	n.a.
ADONA	<LOD	<LOD	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.

MeFOSAA	0.028	0.038	0.0052	0.0058	0.0048
EtFOSAA	0.0027	0.0092	<LOD	0.0035	<LOD
diSAMPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 diPAP	<LOD	<LOD	0.038	<LOD	<LOD
8:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2/8:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.051	0.10	0.050	0.15	0.13

172

173

174 Table S9: PFAS concentrations of the placental pool tissue samples plaT-K to plaT-M in ng/g (not
 175 concentrated value, so the concentrations represents the mean of each single sample in the
 176 respective pool) – the number in the “()” represents the number of samples which were pooled
 177 together

Summary of the concentrations [ng/g] of pooled placental tissue from K-M			
Compound	plaT-K (3)	plaT-L (3)	plaT-M (2)
PFBA	<LOD	<LOD	0.032
PFPeA	<LOD	<LOD	<LOD
PFHxA	<LOD	<LOD	<LOD
PFHpA	<LOD	0.014	0.016
PFOA	0.36	0.37	0.55
PFNA	0.13	0.077	0.099
PFDA	0.082	0.034	0.053
PFUnDA	0.073	0.032	0.031
PFDoDA	0.028	0.010	0.018
PFTrDA	0.033	0.021	<LOD
PFTDA	0.034	0.019	0.055
PFHxDA	n.a.	n.a.	n.a.

PFOcDA	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD
PFPeS	<LOD	<LOD	<LOD
PFHxS	0.084	0.11	0.14
PFHpS	0.0065	0.010	0.013
L-PFOS	0.47	0.28	0.50
PFNS	n.a.	n.a.	n.a.
PFDS	<LOD	<LOD	<LOD
PFDoDS	<LOD	<LOD	<LOD
PFECHS	n.a.	n.a.	n.a.
FBSA	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD
FOSA	n.a.	n.a.	n.a.
MeFOSA	n.a.	n.a.	n.a.
EtFOSA	n.a.	n.a.	n.a.
MeFOSE	n.a.	n.a.	n.a.
EtFOSE	n.a.	n.a.	n.a.
3:3 FTCA	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD
7:3 FTCA	0.015	0.011	0.015
6:2 FTUCA	<LOD	<LOD	<LOD
8:2 FTUCA	n.a.	n.a.	n.a.
10:2 FTUCA	n.a.	n.a.	n.a.
4:2 FTSA	0.011	0.0055	0.0089
6:2 FTSA	<LOD	<LOD	<LOD
8:2 FTSA	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.
PFDPA	n.a.	n.a.	n.a.

6:6 PFPiA	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD
6:2 Cl-PFESA	n.a.	n.a.	n.a.
ADONA	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.
MeFOSAA	0.0069	0.0050	0.012
EtFOSAA	0.011	0.0027	<LOD
diSAmPAP	<LOD	<LOD	<LOD
6:2 monoPAP	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.
10:2 monoPAP	n.a.	n.a.	n.a.
6:2 diPAP	<LOD	<LOD	<LOD
8:2 diPAP	<LOD	<LOD	<LOD
6:2/8:2 diPAP	<LOD	<LOD	<LOD
10:2 diPAP	n.a.	n.a.	n.a.
PFOS-branch Σ	0.090	0.061	0.12

178

179

180 Table S10: PFAS concentrations of the cord serum pool samples cordS-B to cordS-H in ng/mL (not
 181 concentrated value, so the concentrations represents the mean of each single sample in the
 182 respective pool) – the number in the “()” represents the number of samples which were pooled
 183 together

Summary of the concentrations [ng/mL] of pooled cord serum from B-H					
Compound	cordS-B (2)	cordS-C (3)	cordS-D (3)	cordS-E (1)	cordS-H (3)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	<LOD	<LOD	<LOD	<LOD	0.011
PFHpA	0.045	0.014	0.026	<LOD	0.019
PFOA	1.40	0.72	0.84	0.093	0.81

PFNA	0.13	0.12	0.17	0.040	0.21
PFDA	0.047	0.037	0.040	<LOD	0.065
PFUnDA	0.020	0.017	0.025	0.039	0.037
PFDoDA	<LOD	0.010	0.010	<LOD	0.015
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0076	0.0064	0.0020	<LOD	0.0044
PPPeS	0.0032	0.0064	0.0025	<LOD	0.0034
PFHxS	0.23	0.24	0.14	<LOQ	0.18
PFHpS	<LOD	0.017	0.010	<LOQ	0.017
L-PFOS	0.32	0.34	0.29	0.13	0.35
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0019	0.0023	0.0027	<LOD	0.0075
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	<LOQ	<LOD	<LOD	<LOD	<LOQ
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD

4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	<LOQ	<LOD	0.0070	<LOD	0.0072
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPDA	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	0.014	0.0076	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	<LOD	<LOQ	0.011	<LOD	0.022
EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOQ
diSAmPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.18	0.17	0.17	0.011	0.14

184

185

186 Table S11: PFAS concentrations of the cord serum pool samples cordS-K to cordS-U in ng/mL (not
 187 concentrated value, so the concentrations represents the mean of each single sample in the
 188 respective pool) – the number in the “()” represents the number of samples which were pooled
 189 together

Summary of the concentrations [ng/mL] of pooled cord serum from K-U						
Compound	cordS-K (3)	cordS-L (3)	cordS-N (3)	cordS-O (2)	cordS-S (3)	cordS-U (2)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.027	<LOD	<LOD	<LOD	<LOD	<LOD
PFHpA	0.032	0.021	0.070	0.061	0.022	0.0065
PFOA	1.42	0.75	0.86	1.08	0.89	0.54
PFNA	0.29	0.084	0.11	0.23	0.13	0.098
PFDA	0.090	0.026	0.038	0.067	0.040	0.046
PFUnDA	0.073	0.026	0.021	0.047	0.027	0.046
PFDoDA	0.013	<LOD	<LOD	<LOD	<LOQ	<LOQ
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0084	0.0060	0.0099	<LOD	0.0094	0.0046
PFPeS	0.0081	0.0050	0.0053	0.0054	0.0023	<LOD
PFHxS	0.34	0.26	0.20	0.27	0.23	0.28
PFHpS	0.026	0.019	0.014	0.037	0.012	0.020
L-PFOS	0.62	0.21	0.31	0.84	0.34	0.47
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0027	0.0032	0.0016	0.0022	0.0019	< LOQ
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD

FOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	0.0050	<LOD	<LOD	<LOD	<LOQ	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	0.013	0.0072	0.0045	0.010	0.0070	0.0065
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	0.021	0.027	0.027	0.0094	0.0039	0.0053
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	<LOD	<LOD	0.0051	0.016	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOD	0.17	<LOD	<LOD
diSAMPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD

8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.31	0.15	0.14	0.29	0.15	0.25

190

191 Table S12: Blanks (BW): for BW 1 and BW 2 3 mL Milli Q Water (MQ) were used, for BW 3 2 mL
 192 bovine serum (b.s.) was used, for BW 4 bovine serum spiked with inorganic fluorine (inorg. F), and for
 193 BW 5 2 mL bovine serum spiked with inorganic fluorine but without the additional washing step with 18
 194 mL 0.01% ammonium solution in MQ (no add w.).

Concentrations of the blanks 1-5 for the pooled serum samples					
Compound	BW 1 (3 mL MQ)	BW 2 (3 mL MQ)	BW 3 (2 mL b.s.)	BW 4 (inorg. F)	BW 5 (no add w.)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.0054	0.0087	0.0091	0.0096	<LOD
PFHpA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOA	0.0042	0.0068	0.0086	0.0075	<LOD
PFNA	<LOD	<LOD	0.028	0.025	0.017
PFDA	<LOD	<LOQ	<LOQ	<LOQ	<LOQ
PFUnDA	0.010	0.013	0.0099	<LOQ	<LOD
PFDoDA	0.0017	0.0017	0.0026	0.0026	0.0026
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	0.0012	0.0007	<LOD	<LOD	<LOD
PFPeS	<LOD	<LOD	<LOD	<LOQ	0.0015
PFHxS	<LOQ	0.0046	0.041	0.049	0.040
PFHpS	<LOD	<LOD	0.0021	0.0050	0.0073
L-PFOS	<LOD	<LOD	0.065	0.073	0.072
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.

PFECHS	0.0002	0.0002	0.0003	0.0003	0.0003
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	n.a.	n.a.	n.a.	n.a.	n.a.
FHxSA	<LOD	<LOD	0.0229	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPa	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 CI-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	<LOD	<LOD	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD

diSAmPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	<LOD	<LOD	0.023	0.020	0.024

195

196

197 Table S13: Blanks (BW): for BW 6 and BW 7 3 mL Milli Q Water (MQ) were used, for BW 8 2 mL
 198 bovine serum (b.s.) was used, for BW 9 bovine serum spiked with inorganic fluorine (inorg. F), and for
 199 BW 10 2 mL bovine serum spiked with inorganic fluorine but without the additional washing step with
 200 18 mL 0.01% ammonium solution in MQ (no add w.).

Concentrations of the blanks 6-10 for the pooled serum samples					
Compound	BW 6 (3 mL MQ)	BW 7 (3 mL MQ)	BW 8 (2 mL b.s.)	BW 9 (inorg. F)	BW 10 (no add w.)
PFBA	<LOD	<LOD	<LOD	<LOD	0.21
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	0.015	0.019	0.023	0.021	<LOD
PFHpA	<LOD	<LOD	<LOQ	<LOD	<LOD
PFOA	0.012	0.013	0.016	0.015	<LOQ
PFNA	<LOD	<LOD	0.032	0.031	0.011
PFDA	<LOD	<LOD	0.0215	0.024	<LOQ
PFUnDA	0.0052	0.011	0.017	0.011	0.013
PFDoDA	0.0017	0.0017	0.0026	0.0026	0.0026
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD	<LOD	<LOD

PFPeS	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxS	0.0083	0.012	0.084	0.062	0.061
PFHpS	<LOD	<LOD	<LOD	0.0038	0.0048
L-PFOS	<LOD	<LOD	0.10	0.11	0.11
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0002	0.0002	0.0003	0.0003	0.0003
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxSA	<LOD	<LOD	<LOD	0.039	<LOD
MePFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	0.0058	0.010	0.63	0.61	0.59
8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPa	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.

8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	<LOD	<LOD	0.0030	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.
N-MeFOSAA	<LOD	<LOD	<LOD	<LOQ	<LOD
N-EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD
diSAmPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 diPAP	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.0013	0.0003	0.026	0.033	0.047

201

202

203 Table S14: Blanks (BW): for BW 11 and BW 12 3 mL Milli Q Water (MQ) were used, for BW 13 2 mL
 204 bovine serum (b.s.) was used, for BW 14 and BW 15 bovine serum spiked with inorganic fluorine
 205 (inorg. F), and for BW 16 2 mL bovine serum spiked with inorganic fluorine but without the additional
 206 washing step with 18 mL 0.01% ammonium solution in MQ (no add w.).

Concentrations of the blanks 11-16 for the pooled serum samples						
Compound	BW 11 (3 mL MQ)	BW 12 (3 mL MQ)	BW 13 (2 mL b.s.)	BW 14 (inorg. F)	BW 15 (inorg. F)	BW 16 (no add w.)
PFBA	<LOD	<LOD	<LOD	<LOD	<LOD	0.0571
PFPeA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFHpA	<LOQ	<LOD	<LOD	<LOD	<LOD	<LOD
PFOA	0.013	0.014	0.021	0.021	0.042	0.017
PFNA	<LOD	<LOD	0.021	0.023	0.028	0.010
PFDA	<LOD	<LOD	0.018	<LOQ	0.023	<LOQ

PFUnDA	0.0050	0.0063	0.0095	0.017	0.017	0.0091
PFDoDA	0.0017	0.0017	0.0026	0.0026	0.0026	<LOD
PFTrDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFTDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PPPeS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFHxS	0.0065	0.0096	0.049	0.047	0.11	0.034
PFHpS	<LOD	<LOD	0.0040	0.0045	0.0010	0.0013
L-PFOS	<LOD	<LOD	0.066	0.086	0.070	0.049
PFNS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDS	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFDoDS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFECHS	0.0002	0.0002	0.0003	0.0003	0.0003	0.0035
FBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
FOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
MeFOSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSE	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSE	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
3:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
7:3 FTCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTUCA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
4:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	0.0045	0.0045	0.40	0.39	0.46	0.36

8:2 FTSA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFDPA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
ADONA	<LOD	0.0015	<LOD	<LOD	<LOD	<LOD
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
MeFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
diSAMPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	n.n.	n.n.	n.n.	n.n.	n.n.	n.n.
6:2 diPAP	n.n.	n.n.	n.n.	n.n.	n.n.	n.n.
8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6:2/8:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
10:2 diPAP	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	0.0000	0.0028	0.030	0.024	0.015	0.013

207

208

209 Table S15: Blanks (BW): for BW 1 and BW 3 3 mL Milli Q Water (MQ) were used spiked with inorganic
 210 fluorine (inorg. F), and for BW 2 and BW 4 3 mL MQ were used without the addition of inorganic
 211 fluorine.

Concentrations of the blanks 1-4 for the pooled placental tissue samples				
Compound	BW 1 (3 mL MQ, inorg. F)	BW 2 (no inorg. F)	BW 3 (3 mL MQ, inorg. F)	BW 4 (no inorg. F)
PFBA	<LOQ	<LOQ	<LOD	<LOD

PFPeA	<LOD	<LOD	<LOD	<LOD
PFHxA	0.012	0.011	0.014	0.0077
PFHpA	<LOQ	<LOD	<LOD	<LOD
PFOA	0.011	0.010	0.016	0.016
PFNA	0.0026	0.0020	0.0043	0.0057
PFDA	<LOD	<LOQ	<LOQ	<LOQ
PFUnDA	0.016	0.015	0.015	0.020
PFDoDA	<LOD	<LOD	<LOD	<LOD
PFTrDA	<LOD	<LOD	<LOD	<LOD
PFTDA	<LOD	<LOD	<LOD	<LOD
PFHxDA	n.a.	n.a.	n.a.	n.a.
PFOcDA	n.a.	n.a.	n.a.	n.a.
PFBS	<LOD	<LOD	<LOD	<LOD
PFPeS	<LOD	<LOD	<LOD	<LOD
PFHxS	0.0083	0.0076	0.012	0.016
PFHpS	<LOD	<LOD	<LOD	<LOD
L-PFOS	<LOD	<LOD	<LOD	<LOD
PFNS	n.a.	n.a.	n.a.	n.a.
PFDS	<LOD	<LOD	<LOD	<LOD
PFDoDS	<LOD	<LOD	<LOD	<LOD
PFECHS	n.a.	n.a.	n.a.	n.a.
FBSA	<LOD	<LOD	<LOD	<LOD
MeFBSA	<LOD	<LOD	<LOD	<LOD
FHxSA	<LOD	<LOD	<LOD	<LOD
MeFHxSA	<LOD	<LOD	<LOD	<LOD
FOSA	n.a.	n.a.	n.a.	n.a.
MeFOSA	n.a.	n.a.	n.a.	n.a.
EtFOSA	n.a.	n.a.	n.a.	n.a.
MeFOSE	n.a.	n.a.	n.a.	n.a.
EtFOSE	n.a.	n.a.	n.a.	n.a.
3:3 FTCA	<LOD	<LOD	<LOD	<LOD
5:3 FTCA	<LOD	<LOD	<LOD	<LOD

7:3 FTCA	<LOD	<LOD	<LOD	<LOD
6:2 FTUCA	<LOD	<LOD	<LOD	<LOD
8:2 FTUCA	n.a.	n.a.	n.a.	n.a.
10:2 FTUCA	n.a.	n.a.	n.a.	n.a.
4:2 FTSA	<LOD	<LOD	<LOD	<LOD
6:2 FTSA	<LOD	<LOD	<LOD	<LOD
8:2 FTSA	<LOD	<LOD	<LOD	<LOD
10:2 FTSA	n.a.	n.a.	n.a.	n.a.
PFHxPA	<LOD	<LOD	<LOD	<LOD
PFOPA	n.a.	n.a.	n.a.	n.a.
PDFPA	n.a.	n.a.	n.a.	n.a.
6:6 PFPiA	<LOD	<LOD	<LOD	<LOD
6:8 PFPiA	n.a.	n.a.	n.a.	n.a.
8:8 PFPiA	n.a.	n.a.	n.a.	n.a.
8:2 Cl-PFESA	<LOD	<LOD	<LOD	<LOD
6:2 Cl-PFESA	n.a.	n.a.	n.a.	n.a.
ADONA	0.017	0.046	0.017	0.046
HFPO-DA (GenX)	n.a.	n.a.	n.a.	n.a.
MeFOSAA	<LOD	<LOD	<LOD	<LOD
EtFOSAA	<LOD	<LOD	<LOD	<LOD
diSAMPAP	<LOD	<LOD	<LOD	<LOD
6:2 monoPAP	n.a.	n.a.	n.a.	n.a.
8:2 monoPAP	n.a.	n.a.	n.a.	n.a.
10:2 monoPAP	n.a.	n.a.	n.a.	n.a.
6:2 diPAP	<LOD	<LOD	<LOD	<LOD
8:2 diPAP	<LOD	<LOD	<LOD	<LOD
6:2/8:2 diPAP	<LOD	<LOD	<LOD	<LOD
10:2 diPAP	n.a.	n.a.	n.a.	n.a.
PFOS-branch Σ	<LOD	<LOD	<LOD	<LOD

213 **Extractable organofluorine (EOF) concentrations of the samples**

214 The extractable organofluorine concentrations for all sample pools are provided in
215 Table S16 to Table S18. Table S19 provides detailed information on the sample
216 pooling and Table S20 shows extractable organofluorine concentrations from other
217 studies compared to the present one.

218

219 Maternal serum (matS).

220 Table S16: Identified EOF in ng F/mL in maternal serum (matS). The LOQ was 2.7 ng F/mL except for
221 the samples matS-B, matS-C, matS-E to matS-O, and matS-U, where the background noise
222 inbetween the samples was higher and therefore no values of the CIC for those samples are available.

Sample name	CIC-EOF [ng F/mL]	Targeted [ng F/mL]	Identified [%]
matS-A	2.85	3.11	109.07
matS-B	<LOQ	2.74	
matS-C	<LOQ	3.16	
matS-D	2.90	2.53	87.12
matS-E	<LOQ	5.87	
matS-F	<LOQ	1.78	
matS-G	<LOQ	2.19	
matS-H	<LOQ	3.10	
matS-I	<LOQ	4.70	
matS-J	<LOQ	6.24	
matS-K	<LOQ	3.21	
matS-L	<LOQ	2.50	
matS-M	<LOQ	3.34	
matS-N	<LOQ	2.71	
matS-O	<LOQ	6.88	
matS-P	3.59	2.33	64.97
matS-Q	<LOQ	2.08	
matS-R	7.17	2.77	38.68
matS-S	2.99	2.08	69.50

matS-T	3.46	3.10	89.46
matS-U	<LOQ	3.47	

223

224 Placental tissue (plaT).

225 Table S17: Identified EOF in ng F/mL in placental tissue (plaT). The LOQ was 0.92 ng F/mL, except
 226 for plaT-I and plaT-J where the background noise inbetween the samples was higher and therefore no
 227 values of the CIC for those samples are available.

Sample name	CIC-EOF [ng F/g]	Targeted [ng F/g]	Identified [%]
plaT-A	1.43	0.57	39.43
plaT-B	1.08	0.53	49.13
plaT-C	1.07	0.53	49.40
plaT-D	1.85	0.77	41.49
plaT-E	<LOQ	0.88	
plaT-F	<LOQ	0.34	
plaT-G	<LOQ	0.78	
plaT-H	1.02	0.58	57.32
plaT-I	<LOQ	0.92	
plaT-J	<LOQ	1.36	
plaT-K	1.08	0.62	57.64
plaT-L	<LOQ	0.45	
plaT-M	<LOQ	0.74	

228

229 Cord serum (cordS).

230 Table S18: Identified EOF in ng F/mL in cord serum (cordS). The LOQ was 1.1 ng F/mL, except for
 231 cord-B and cord-S where the background noise inbetween the samples was higher and therefore no
 232 values of the CIC for those samples are available.

Sample name	EOF-CIC [ng F/mL]	Targeted [ng F/mL]	Identified [%]
cordS-B	<LOQ	1.77	
cordS-C	1.80	1.20	66.65
cordS-D	1.20	1.18	97.90
cordS-E	<LOQ	0.33	

cordS-H	1.36	1.27	93.53
cordS-K	2.10	2.23	106.28
cordS-L	<LOQ	1.06	
cordS-N	1.20	1.23	101.99
cordS-O	2.03	2.11	104.12
cordS-S	<LOQ	1.26	
cordS-U	1.80	1.24	69.04

233

234

235 Table S19: Detail information on the sample pooling – sample pools for which the EOF concentration was <LOQ are marked with a “*” and “n.a.”

236 was used if a sample pool was not available (e.g. not enough sample volume available for pooling)

Sample	Quantity of samples for pooling (sera; placenta)	matS [µL]	plaT [g]	cordS [µL]	Gender (child)	City	Weight [g]	Classification	Health
A	3 x 600 µL; 3 x 1.5 g	1800	4.5	n.a.	female	St. Pölten (STP)	≤2850	SGA	ok
B	2 x 600 µL (2); 2 x 3 g	1200	6	1200	female	Tulln (TU)	>2850	AGA	ok
C	3 x 600 µL (2); 3 x 2g	1800	6	1800	female	Tulln	>2850	AGA	ok
D	3 x 600 µL (2); 3 x 1.5 g	1800	4.5	1800	female	Tulln	>2850	AGA	ok
E	1 x 600 µL (2); 1 x 6 g	600	6*	600*	female	St. Pölten	>2850	AGA	ok
F	4 x 600 µL; 4 x 1.5 g	2400	6	n.a.	female	Tulln	>2850	AGA	ok
G	2 x 600 µL; 2 x 3 g	1200	6	n.a.	male	St. Pölten	>2850	AGA	PE
H	3 x 600 µL (2); 3 x 1.5 g	1800	4.5	1800	male	St Pölten	≤2850	SGA	ok
I	1 x 600 µL; 1 x 4.5 g	600	4.5*	n.a.	male	St. Pölten	≤2850	AGA	ok
J	2 x 600 µL; 2 x 2.25 g	1200	4.5	n.a.	male	Tulln	>2850	AGA	ok
K	3 x 600 µL (2); 3 x 1.5 g	1800	4.5	1800	male	Tulln	>2850	AGA	ok
L	3 x 600 µL (2); 3 x 1.5 g	1800	4.5*	1200*	male	Tulln	>2850	AGA	ok
M	2 x 600 µL; 2 x 1.5 g	1200	3	n.a.	male	Tulln	>2850	AGA	ok
N	3 x 600 µL (2)	1800	n.a.	1800	female	Tulln	>2850	AGA	GDM
O	2 x 600 µL (2)	1200	n.a.	1200	female	Tulln	mix	AGA	FG
P	3 x 600 µL	1800	n.a.	n.a.	female	Wien / STP	mix	AGA	FG
Q	3 x 600 µL	1800	n.a.	n.a.	female	Wien	>2850	AGA	ok
R	3 x 600 µL	1800	n.a.	n.a.	female	Wien	>2850	AGA	ok
S	3 x 600 µL (2)	1800	n.a.	1800*	male	Tulln	>2850	AGA	GDM

T	3 x 600 µL	1800	n.a.	n.a.	male	Wien / STP / TU	mix	AGA	FG
U	2 x 600 µL (2)	1200	n.a.	1200	male	Wien / TU	>2850	LGA	ok

237

238

239 Table S20: The comparison of EOF concentrations in ng F/mL of the present study with previous studies


Study	Year of sampling	Country	matS (or others) [ng F/mL]	plaT [ng F/g]	cordS [ng F/mL]
Present study	2019-2020	Austria	2.85 – 7.17	1.02 – 1.85	1.2 – 2.10
Yeung and Mabury (2016) ¹	2004	China	8.22 – 94.4 (whole blood, male and female)		
Yeung and Mabury (2016) ¹	1982-2009	Germany	9.42 – 42.5 (plasma, male and female)		
Miaz et al. (2020) ²	1996-2017	Sweden	8.1 – 32.0 ng F/ g (serum, females)		
Yeung et al. (2008) ³	2004	China	< 6 – 43.4 (whole blood, male and female)		
Miyake et al., (2007) ⁴	2003-2004	Japan	< 6 – 8.9 (whole blood and serum, males)		
Miyake et al., (2007) ⁴	2001	USA	17.8 – 59 (plasma, males)		

240

241


242 **Correlation analyses and scatter plots**

243 Figures S2 to S7 show the scatter plots for the total EOF levels (EOF-CIC)
244 determined on the CIC and individual target compound levels for matS and plaT
245 converted to their fluorine equivalents. Additionally, scatter plots are shown for
246 unidentified EOF levels (EOF-unid) and individual target compounds. For the scatter
247 plots, the results from the concentrated samples were used, however, the outcome
248 after adjusting to the orginial sample pool volumes is equal. The figures also show
249 the Spearmen correlation coefficienties (r_s) and the p-values. The grey zone
250 represents the 95% confidence interval.



251


252 Figure S2: Correlation between PFBA and EOF-CIC, and between PFBA and EOF-unid in plaT.



253



254 Figure S3: Correlation between MeFOSAA and EOF-CIC, and between MeFOSAA and EOF-unid in

255 plaT.



256



257 Figure S4: Correlation between 3:3 FTCA and EOF-CIC, and between br-PFOS and EOF-CIC in plaT.



258

259 Figure S5: Correlation between PFOS and EOF-CIC, and between PFOA and EOF-unid in matS.


260



261

262 Figure S6: Correlation between 6:2 FTSA and EOF-CIC, and between 6:2 FTSA and EOF-unid in
263 matS.

264



265

266 Figure S7: Correlation between PFECHS and EOF-CIC in matS.

267

268 **Abbreviations**

269

270 6:2 Cl-PFESA 6:2 chlorinated polyfluorinated ether sulfonate (major F-53B)

271 6:6 PFPiA bis(perfluorohexyl)phosphinate (bis(perfluorohexyl)phosphinic acid)

273 6:8 PFPiA perfluorohexyl-perfluoroctyl phosphinate (perfluorohexyl-perfluoroctyl phosphinic acid)

275 8:2 Cl-PFESA 8:2 chlorinated polyfluorinated ether sulfonate (minor F-53B)

276 8:2 monoPAP 8:2 polyfluoroalkyl phosphate monoester

277 8:8 PFPiA bis(perfluoroctyl)phosphinate (bis(perfluoroctyl)phosphinic acid)

279 ADONA dodecalfluoro-3H-4,8-dioxanonanoate

280 CIC combustion ion chromatography

281 diPAPs polyfluoroalkyl phosphate diesters

282 diSAMPAP (bis-)2-N-ethylperfluoroctane-n-sulfonamido-ethyl-phosphate
283 EOF extractable organofluorine

284 ESI electrospray ionization

285 EtFOSA N-ethyl-perfluoro-n-octane sulfonamide

286 EtFOSAA N-ethyl-perfluoro-n-octane sulfonamido acetic acid

287 EtFOSE N-ethyl-perfluoro-n-octane sulfonamido ethanol

288 FBSA perfluoro-n-butane sulfonamide

289 FHxSA perfluoro-n-hexane sulfonamide

290 FOSA perfluoro-n-octane sulfonamide

291 FOSAs perfluoroalkyl sulfonamides

292 FOSEs perfluoroalkyl sulfonamidoethanols

293 FTCAs fluorotelomer carboxylate (fluorotelomer carboxylic acids)

294	FTOHs	fluorotelomer alcohols
295	FTSAs	fluorotelomer sulfonate (fluorotelomer sulfonic acids)
296	FTUCAs	fluorotelomer unsaturated carboxylates (fluorotelomer
297		unsaturated carboxylic acids)
298	fTW	filtered-tap-water
299	HF	hydrogen fluoride
300	HFPO-DA	hexafluoropropylene oxide dimer acid (GenX)
301	HPLC-MS/MS	high-performance liquid chromatography tandem-mass
302		spectrometry
303	MeFBSA	N-methyl-perfluorobutane sulfonamide
304	MeFHxSA	N-methyl-perfluoro-n-hexane sulfonamide
305	MeFOSA	N-methyl-perfluoro-n-octane sulfonamide
306	MeFOSAA	N-methyl-perfluoro-n-octane sulfonamido acetic acid
307	MeFOSE	N-methyl-perfluoro-n-octane sulfonamido ethanol
308	monoPAPs	polyfluoroalkyl phosphate monoesters
309	OBS	p-perfluous noneoxybenzenesulfonate
310	PAPs	polyfluoroalkyl phosphate esters
311	PASF	perfluoroalkyl sulfonyl fluoride
312	PFAAs	perfluoroalkyl acids
313	PFBA	perfluoro-n-butane carboxylate (perfluoro-n-butanoic acid)
314	PFBS	perfluoro-n-butane sulfonate (perfluoro-n-butane sulfonic acid)
315	PFCAs	perfluoroalkyl carboxylates (perfluoroalkyl carboxylic acids)
316	PFDA	perfluoro-n-decane carboxylate (perfluoro-n-decanoic acid)
317	PFDoDA	perfluoro-n-dodecane carboxylate (perfluoro-n-dodecanoic acid)
318	PFDoDS	perfluoro-n-dodecane sulfonate (perfluoro-n-dodecane sulfonic acid)
319		

320	PFDPA	perfluorodecyl phosphonate (perfluorodecyl phosphonic acid)
321	PFDS	perfluoro-n-decane sulfonate (perfluoro-n-decane sulfonic acid)
322	PFECAs	perfluoroalkyl ether carboxylates (perfluoroalkyl ether carboxylic acids)
323		
324	PFECHS	perfluoro-4-ethylcyclohexane sulfonate
325	PFESAs	perfluoroalkyl ether sulfonates (perfluoroalkyl ether sulfonic acids)
326		
327	PFHpA	perfluoro-n-heptane carboxylate (perfluoro-n-heptanoic acid)
328	PFHpS	perfluoro-n-heptane sulfonate (perfluoro-n-heptane sulfonic acid)
329	PFHxA	perfluoro-n-hexane carboxylate (perfluoro-n-hexanoic acid)
330	PFHxDA	perfluoro-n-hexadecane carboxylate (perfluoro-n-hexadecanoic acid)
331		
332	PFHxPA	perfluorohexyl phosphonate (perfluorohexyl phosphonic acid)
333	PFHxS	perfluoro-n-hexane sulfonate (perfluoro-n-hexane sulfonic acid)
334	PFNA	perfluoro-n-nonane carboxylate (perfluoro-n-nonanoic acid)
335	PFNS	perfluoro-n-nonane sulfonate (perfluoro-n-nonane sulfonic acid)
336	PFOA	perfluoro-n-octane carboxylate (perfluoro-n-octanoic acid)
337	PFOcDA	perfluoro-n-octadecane carboxylate (perfluoro-n-octadecanoic acid)
338		
339	PFOPA	perfluorooctyl phosphonate (perfluorooctyl phosphonic acid)
340	PFOS	perfluoro-n-octane sulfonate (perfluoro-n-octane sulfonic acid)
341	PFPAs	perfluoroalkyl phosphonate (perfluoroalkyl phosphonic acids)
342	PFPeA	perfluoro-n-pentane carboxylate (perfluoro-n-pentanoic acid)
343	PFPeS	perfluoro-n-pentane sulfonate (perfluoro-n-pentane sulfonic acid)
344	PPPiAs	perfluoroalkyl phosphinates (perfluoroalkyl phosphinic acids)
345	PFSAs	perfluoroalkyl sulfonates (perfluoroalkane sulfonic acids)

346	PFTeDA	perfluoro-n-tetradecane carboxylate (perfluoro-n-tetradecanoic acid)
347		
348	PFTrDA	perfluoro-n-tridecane carboxylate (perfluoro-n-tridecanoic acid)
349	PFUnDA	perfluoro-n-undecane carboxylate (perfluoro-n-undecanoic acid)
350	POPs	persistent organic pollutants
351	SPE-HLB	solid phase extraction with hydrophilic lipophilic balance
352	SPE-WAX	solid phase extraction with weak anion exchange
353	TTEs	transplacental transfer efficiencies
354	UPLC	ultra-performance liquid chromatography
355		

356 **References**

- 357 (1) Yeung, L. W. Y.; Mabury, S. A. Are Humans Exposed to Increasing Amounts of
358 Unidentified Organofluorine. **2016**, *Environmental Chemistry*, 102–110.
- 359 (2) Miaz, L. T.; Plassmann, M. M.; Gyllenhammar, I.; Bignert, A.; Sandblom, O.;
360 Lignell, S.; Glynn, A.; Benskin, J. P. Temporal Trends of Suspect- and Target-
361 per/Polyfluoroalkyl Substances (PFAS), Extractable Organic Fluorine (EOF) and
362 Total Fluorine (TF) in Pooled Serum from First-Time Mothers in Uppsala,
363 Sweden, 1996–2017. **2020**, *Environmental Science Processes and Impacts* 22,
364 1071–1083. <https://doi.org/10.1039/C9EM00502A>.
- 365 (3) Yeung, L. W. Y.; Miyake, Y.; Taniyasu, S.; Wang, Y.; Yu, H.; So, M. K.; Jiang,
366 G.; Wu, Y.; Li, J.; Giesy, J. P.; Yamashita, N.; Lam, P. K. S. Perfluorinated
367 Compounds and Total and Extractable Organic Fluorine in Human Blood
368 Samples from China. **2008**, *Environmental Science and Technology* 42 (21),
369 8140–8145. <https://doi.org/10.1021/es800631n>.
- 370 (4) Miyake, Y.; Yamashita, N.; Rostkowski, P.; Taniyasu, S.; Lam, P. K. S.; Kannan,
371 K. Trace Analysis of Total Fluorine in Human Blood Using Combustion Ion
372 Chromatography for Fluorine: A Mass Balance Approach for the Determination
373 of Known and Unknown Organofluorine Compounds. **2007**, *Journal of
374 Chromatography A* 1154, 214–221.
375